
CLAIMS

1. Use of a sigma ligand for the manufacture of a medicament for treatment and/or prevention of type-2 diabetes-associated pain,
wherein the sigma ligand has the general formula (I):



(I)

wherein

R_1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_3 and **R_4** are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, -

COR_8, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, -CN, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together they form an optionally substituted fused ring system;

R_5 and **R_6** are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, -CN, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group;

n is selected from 1, 2, 3, 4, 5, 6, 7 and 8;

t is 1,2 or 3;

R_8 and **R_9** are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen;

wherein the substituted groups are substituted at one or more available positions by one or more groups selected from the group consisting of halogen; cyano; hydroxyl; nitro; azido; acyl; carboxamido; alkyl; alkenyl; alkynyl; alkoxy; aryloxy; alkylthio; alkylsulfinyl; alkylsulfonyl; aminoalkyl; carbocyclic aryl and aralkyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. Use of a sigma ligand according to claim 1, wherein the type-2 diabetes-associated pain is derived from diabetic neuropathy, diabetic retinopathy, diabetic amyotrophy, gastroparesis, diabetic diarrhea, charcot joint, neuropathy of the bladder, diabetic nephropathy and/or diabetic foot problems.

3. Use of a sigma ligand according to any of claims 1 or 2, which is selected from a sigma receptor antagonist preferably selected from a neutral antagonist, an inverse agonist and a partial antagonist.

4. Use of a sigma ligand according to any of claims 1 to 3, wherein R_1 is selected from H, $-COR_8$ and substituted or unsubstituted alkyl.

5. Use of a sigma ligand according to any of claims 1 to 4, wherein R_2 is H or alkyl.

6. Use of a sigma ligand according to any of claims 1 to 5, wherein R_3 and R_4 together form a fused naphthyl ring system.

7. Use of a sigma ligand according to any of claims 1 to 6, wherein R_5 and R_6 together form a morpholine-4-yl group.

8. Use of a sigma ligand according to claim 1, which is selected from the group consisting of:

[1] 4-{2-(1-(3,4-Dichlorophenyl)-5-methyl-1H pyrazol-3-yloxy)ethyl}morpholine

[2] 2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine

[3] 1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[4] 1-(3,4-Dichlorophenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[5] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[6] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole

[7] 3-{1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H-imidazo [4,5-b]pyridine

[8] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-4-methylpiperazine

[9] Ethyl 4-{2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperazine carboxylate

[10] 1-(4-(2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone

[11] 4-{2-[1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[12] 1-(4-Methoxyphenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[13] 1-(4-Methoxyphenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[14] 1-[2-(1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidine

[15] 1-{2-[1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole

[16] 4-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[17] 1-(3,4-Dichlorophenyl)-5-phenyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[18] 1-(3,4-Dichlorophenyl)-5-phenyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[19] 1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[20] 1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole

[21] 2-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}-1,2,3,4-tetrahydroisoquinoline

[22] 4-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}morpholine

[23] 1-(3,4-Dichlorophenyl)-5-methyl-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole

[24] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}piperidine

[25] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-4-methylpiperazine

[26] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-1H-imidazole

[27] 4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine

[28] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-4-phenylpiperidine

[29] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-6,7-dihydro-1H-indol-4(5H)-one

[30] 2-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-1,2,3,4-tetrahydroisoquinoline

[31] 4-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[32] 2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine

[33] 1-(3,4-Dichlorophenyl)-5-isopropyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[34] 1-(3,4-Dichlorophenyl)-5-isopropyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[35] 1-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[36] 2-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]ethyl}-1,2,3,4-tetrahydroisoquinoline

[37] 4-{2-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]ethyl}morpholine

[38] 2-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy] N,N-diethylethanamine

[39] 1-(3,4-Dichlorophenyl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[40] 1-{2-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]ethyl}piperidine

[41] 1-(3,4-Dichlorophenyl)-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[42] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperazine

[43] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}pyrrolidin-3-amine

[44] 4-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[45] 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine

[46] 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[47] 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[48] 1-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[49] 4-{4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}morpholine

[50] (2S,6R)-4-{4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}-2,6-dimethyl morpholine

[51] 1-{4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}piperidine

[52] 1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole

[53] 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine

[54] N-benzyl-4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-methylbutan-1-amine

[55] 4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1-amine

[56] 4-{4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}thiomorpholine

[57] 1-[1-(3,4-Dichlorophenyl)-5-methyl-3-(2-morpholinoethoxy)-1H-pyrazol-4-yl] ethanone

[58] 1-{1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazol-4-yl} ethanone

[59] 1-{1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(piperidin-1-yl)ethoxy]-1H-pyrazol-4-yl} ethanone

[60] 1-{1-(3,4-Dichlorophenyl)-3-[2-(diethylamino)ethoxy]-5-methyl-1H-pyrazol-4-yl} ethanone

[61] 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine

[62] N,N-Diethyl-2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethanamine

[63] 1-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}piperidine

[64] 5-Methyl-1-(naphthalen-2-yl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

or a pharmaceutically acceptable salt or solvate thereof.

9. Use of a sigma ligand according to any of claims 1 to 8, which is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine, or a pharmaceutically acceptable salt or solvate thereof.

10. Use of a sigma ligand according to claim 9, which is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

11. Use of a combination of at least one sigma ligand as defined in any of claims 1 to 10 and at least one further active substance for the manufacture of a medicament for the treatment and/or prevention of type-2 diabetes-associated pain, wherein the at least one further active substance is selected from the group consisting of oxycodone, tramadol, tapentadol, morphine, hydrocodone, codeine, buprenorfine, fentanyl, remifentanyl, sufentanyl, pregabalin, gabapentin, retigabine, duloxetine,

amitriptyline, venlafaxine, ibuprofen, diclofenac, naproxen, aspirin, desketoprofen, ketoprofen, celecoxib, clonidine, ketamine and memantine.


CLAIMS

1. A sigma ligand for use in the treatment and/or prevention of type-2 diabetes-associated pain.

2. Sigma ligand according to claim 1, wherein the type-2 diabetes-associated pain is derived from diabetic neuropathy, diabetic retinopathy, diabetic amyotrophy, gastroparesis, diabetic diarrhea, charcot joint, neuropathy of the bladder, diabetic nephropathy and/or diabetic foot problems.

3. Sigma ligand according to any of claims 1 to 2, which is selected from a sigma receptor antagonist preferably selected from a neutral antagonist, an inverse agonist and a partial antagonist.

4. Sigma ligand according to any of claims 1 to 3, having the general formula (I):



(I)

wherein

R_1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_3 and R_4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together they form an optionally substituted fused ring system;

R_5 and R_6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group;

n is selected from 1, 2, 3, 4, 5, 6, 7 and 8;

t is 1,2 or 3;

R_8 and R_9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen;

or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

5. Sigma ligand according to claim 4, wherein R_1 is selected from H, -COR_8 and substituted or unsubstituted alkyl.

6. Sigma ligand according to claims 4 or 5, wherein R_2 is H or alkyl.

7. Sigma ligand according to any of claims 4 to 6, wherein R_3 and R_4 together form a fused naphthyl ring system.

8. Sigma ligand according to any of claims 4 to 7, wherein R_5 and R_6 together form a morpholine-4-yl group.

9. Sigma ligand according to claim 4, which is selected from the group consisting of:

[1] 4-{2-(1-(3,4-Dichlorophenyl)-5-methyl-1H pyrazol-3-yloxy)ethyl}morpholine

[2] 2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine

[3] 1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[4] 1-(3,4-Dichlorophenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[5] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[6] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole

[7] 3-{1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H-imidazo [4,5-b]pyridine

[8] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-4-methylpiperazine

[9] Ethyl 4-{2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperazine carboxylate

[10] 1-(4-(2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone

[11] 4-{2-[1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[12] 1-(4-Methoxyphenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[13] 1-(4-Methoxyphenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[14] 1-[2-(1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidine

[15] 1-{2-[1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole

[16] 4-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[17] 1-(3,4-Dichlorophenyl)-5-phenyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[18] 1-(3,4-Dichlorophenyl)-5-phenyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[19] 1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[20] 1-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole

[21] 2-{2-[1-(3,4-Dichlorophenyl)-5-phenyl-1H-pyrazol-3-yloxy]ethyl}-1,2,3,4-tetrahydroisoquinoline

[22] 4-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}morpholine

[23] 1-(3,4-Dichlorophenyl)-5-methyl-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole

[24] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}piperidine

[25] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-4-methylpiperazine

[26] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-1H-imidazole

[27] 4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine

[28] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-4-phenylpiperidine

[29] 1-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-6,7-dihydro-1H-indol-4(5H)-one

[30] 2-{4-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]butyl}-1,2,3,4-tetrahydroisoquinoline

[31] 4-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[32] 2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine

[33] 1-(3,4-Dichlorophenyl)-5-isopropyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[34] 1-(3,4-Dichlorophenyl)-5-isopropyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[35] 1-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[36] 2-{2-[1-(3,4-Dichlorophenyl)-5-isopropyl-1H-pyrazol-3-yloxy]ethyl}-1,2,3,4-tetrahydroisoquinoline

[37] 4-{2-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]ethyl}morpholine

[38] 2-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy] N,N-diethylethanamine

[39] 1-(3,4-Dichlorophenyl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[40] 1-{2-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]ethyl}piperidine

[41] 1-(3,4-Dichlorophenyl)-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[42] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperazine

[43] 1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}pyrrolidin-3-amine

[44] 4-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl}morpholine

[45] 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine

[46] 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

[47] 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole

[48] 1-{2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl}piperidine

[49] 4-{4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}morpholine

[50] (2S,6R)-4-{4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}-2,6-dimethyl morpholine

[51] 1-{4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}piperidine

[52] 1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole

[53] 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine

[54] N-benzyl-4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-methylbutan-1-amine

[55] 4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1-amine

[56] 4-{4-[1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}thiomorpholine

[57] 1-[1-(3,4-Dichlorophenyl)-5-methyl-3-(2-morpholinoethoxy)-1H-pyrazol-4-yl] ethanone

[58] 1-{1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazol-4-yl} ethanone

[59] 1-{1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(piperidin-1-yl)ethoxy]-1H-pyrazol-4-yl} ethanone

[60] 1-{1-(3,4-Dichlorophenyl)-3-[2-(diethylamino)ethoxy]-5-methyl-1H-pyrazol-4-yl} ethanone

[61] 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine

[62] N,N-Diethyl-2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethanamine

[63] 1-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}piperidine

[64] 5-Methyl-1-(naphthalen-2-yl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

10. Sigma ligand according to any of claims 5 to 9, which is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

11. Sigma ligand according to claim 10, which is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

12. Use of a sigma ligand as defined in any of claims 1 to 11 for the manufacture of a medicament for the treatment and/or prevention of type-2 diabetes-associated pain.

13. A combination of at least one sigma ligand as defined in any of claims 1 to 11 and at least one further active substance for use in the treatment and/or prevention of type-2 diabetes-associated pain.